Study guide

4.3: Quantitative Pharmacokinetics (Vd, Clearance, Half-life, Steady-state)

Overseas Pharmacist Readiness Assessment OPRA

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1: About the OPRA Exam 1.2: Study and Preparation Strategy for OPRA

2 Chapter 2: Biomedical Sciences

2.1: Human Physiology & Homeostasis 2.2: Pathophysiology of Major Organ Systems 2.3: Medical Microbiology & Infectious Pathogens 2.4: Immunology & Immunotherapy 2.5: Body Fluids, Electrolytes, & Acid-Base Balance 2.6: Physiological Values & Clinical Lab Interpretations

3 Chapter 3: Medicinal Chemistry & Biopharmaceutics

3.1: Physicochemical Properties of Drugs 3.2: Biopharmaceutics & Formulation Science 3.3: Chemical Stability & Storage of Pharmaceuticals 3.4: Sterile Compounding & Pharmaceutical Microbiology

4 Chapter 4: Pharmacokinetics & Pharmacodynamics

4.1: Principles of Pharmacokinetics (Absorption & Distribution) 4.2: Drug Metabolism & Elimination Pathways 4.3: Quantitative Pharmacokinetics (Vd, Clearance, Half-life, Steady-state) 4.4: Clinical Pharmacokinetics (Dosing Adjustments & Non-linear Kinetics) 4.5: Pharmacodynamics & Receptor Theory

5 Chapter 5: Pharmacology & Toxicology

5.1: Mechanisms of Action: Cardiovascular & Renal Agents 5.2: Mechanisms of Action: Respiratory, CNS, & Endocrine Agents 5.3: Adverse Drug Reactions & Drug-Drug Interactions 5.4: Clinical Toxicology & Poisoning Management 5.5: Pharmacogenomics & Genetic Polymorphism

6 Chapter 6: Therapeutics & Patient Care

6.1: Pharmaceutical Calculations: Doses & Unit Conversions 6.2: Pharmaceutical Calculations: Infusions, Percentages, & Tonicity 6.3: Cardiovascular Therapeutics (Hypertension, Heart Failure, Dyslipidemia) 6.4: Anticoagulation & Antiplatelet Therapy 6.5: Endocrine & Metabolic Therapeutics (Diabetes & Thyroid) 6.6: Respiratory Therapeutics (Asthma & COPD) 6.7: Infectious Disease Therapeutics & Antimicrobial Stewardship 6.8: Central Nervous System & Mental Health Therapeutics 6.9: Gastrointestinal & Renal Therapeutics 6.10: Therapeutics in Special Populations: Pregnancy & Lactation 6.11: Therapeutics in Special Populations: Paediatrics & Geriatrics 6.12: Primary Health Care, Self-Care, & Harm Minimisation 6.13: Professional Practice, Ethics, & Communication

4.3: Quantitative Pharmacokinetics (Vd, Clearance, Half-life, Steady-state)

Key Takeaways Explain This Topic AI

Loading dose (LD) is calculated as (Vd * C_target) / F and is used to rapidly achieve therapeutic concentrations for drugs with long half-lives relative to the clinical urgency.

Clearance (Cl) measures the volume of plasma completely cleared of drug per unit time and is related to AUC by Cl = (F * Dose) / AUC.

Half-life (t1/2) is a dependent pharmacokinetic parameter determined by Vd and Cl through the relationship t1/2 = 0.693 * Vd / Cl, which explains why half-life increases in renal impairment or fluid overload.

Steady state is achieved when the rate of drug administration equals the rate of elimination, requiring approximately 4 to 5 half-lives of regular dosing to be established.

Maintenance dose (MD) is calculated as (Cl * C_target * tau) / F, where tau represents the dosing interval, and must be adjusted dynamically based on renal and hepatic clearance.

Last updated: July 2026

4.3: Quantitative Pharmacokinetics (Vd, Clearance, Half-life, Steady-state)

Quantitative pharmacokinetics involves the mathematical application of pharmacokinetic models to drug dosing, helping clinicians design safe and effective therapeutic regimens.

Volume of Distribution (Vd) and Loading Dose Calculations

The apparent Volume of Distribution ( V d V_d V d ​ ) is defined as: V d = Amount of drug in the body (Dose) C V_d = \frac{\text{Amount of drug in the body (Dose)}}{C} V d ​ = C Amount of drug in the body (Dose) ​

Where C C C is the plasma concentration of the drug. For an extravascular dose with bioavailability F F F : V d = F ⋅ Dose C 0 V_d = \frac{F \cdot \text{Dose}}{C_0} V d ​ = C 0 ​ F ⋅ Dose ​

Loading Dose (LD)

A loading dose is a large initial dose administered to rapidly achieve therapeutic plasma concentrations, bypassing the delay associated with reaching steady state (which takes 4–5 half-lives). Loading doses are used for drugs with long half-lives when an immediate therapeutic effect is critical (e.g., phenytoin in status epilepticus, digoxin in atrial fibrillation, amiodarone). LD = V d ⋅ C target F \text{LD} = \frac{V_d \cdot C_{\text{target}}}{F} LD = F V d ​ ⋅ C target ​ ​

Where:

V d V_d V d ​ is the volume of distribution (expressed in L or L/kg).

C target C_{\text{target}} C target ​ is the desired therapeutic plasma concentration.

F F F is the bioavailability of the drug formulation. For intravenous administration, F = 1 F = 1 F = 1 (or F = S F = S F = S , the salt factor of the drug form).

Worked Clinical Example (Phenytoin):

A patient weighing 80 kg presents with status epilepticus. The target therapeutic concentration of phenytoin is 18 mg/L. The volume of distribution ( V d V_d V d ​ ) of phenytoin is 0.75 L/kg. Phenytoin sodium injection has a salt factor ( S S S ) of 0.92. (For IV phenytoin sodium, F = S = 0.92 F = S = 0.92 F = S = 0.92 ).

Calculate total V d V_d V d ​ : V d = 80 kg ⋅ 0.75 L/kg = 60 L V_d = 80 \text{ kg} \cdot 0.75 \text{ L/kg} = 60 \text{ L} V d ​ = 80 kg ⋅ 0.75 L/kg = 60 L

Calculate the intravenous loading dose: LD = 60 L ⋅ 18 mg/L 0.92 = 1080 mg 0.92 ≈ 1174 mg \text{LD} = \frac{60 \text{ L} \cdot 18 \text{ mg/L}}{0.92} = \frac{1080 \text{ mg}}{0.92} \approx 1174 \text{ mg} LD = 0.92 60 L ⋅ 18 mg/L ​ = 0.92 1080 mg ​ ≈ 1174 mg

Clinical Context: In practice, this would be rounded to 1100–1200 mg and administered intravenously at a rate not exceeding 50 mg/minute (25 mg/minute in elderly patients) in normal saline, with continuous ECG and blood pressure monitoring to avoid severe cardiotoxicity (bradyarrhythmias, hypotension) caused by the propylene glycol solvent.

Clearance (Cl)

Clearance ( C l Cl Cl ) is the volume of plasma completely cleared of a drug per unit time (expressed in L/h or mL/min). Unlike elimination rate, which varies with concentration in first-order kinetics, clearance remains constant. C l = Rate of elimination C Cl = \frac{\text{Rate of elimination}}{C} Cl = C Rate of elimination ​

Clearance and AUC

Clearance can be calculated from the total systemic exposure, represented by the Area Under the Curve (AUC): C l = F ⋅ Dose AUC Cl = \frac{F \cdot \text{Dose}}{\text{AUC}} Cl = AUC F ⋅ Dose ​

Organ Clearance

Total systemic clearance ( C l total Cl_{\text{total}} C l total ​ ) is the sum of clearances by individual eliminating organs: C l total = C l renal + C l hepatic + C l other Cl_{\text{total}} = Cl_{\text{renal}} + Cl_{\text{hepatic}} + Cl_{\text{other}} C l total ​ = C l renal ​ + C l hepatic ​ + C l other ​

Hepating Clearance ( C l H Cl_H C l H ​ ): C l H = Q H ⋅ E H Cl_H = Q_H \cdot E_H C l H ​ = Q H ​ ⋅ E H ​ Where Q H Q_H Q H ​ is hepatic blood flow (approx. 1.5 L/min or 90 L/h) and E H E_H E H ​ is the hepatic extraction ratio.

High Extraction Drugs ( E H > 0.7 E_H > 0.7 E H ​ > 0.7 ): (e.g., morphine, propranolol, verapamil). Clearance is blood-flow limited. Reductions in liver blood flow (e.g., in congestive heart failure, beta-blocker therapy) directly decrease clearance.

Low Extraction Drugs ( E H < 0.3 E_H < 0.3 E H ​ < 0.3 ): (e.g., phenytoin, warfarin). Clearance is capacity-limited and depends on intrinsic liver enzyme activity and the drug's unbound fraction ( f u f_u f u ​ ).

Renal Clearance ( C l R Cl_R C l R ​ ): Renal clearance is calculated using: C l R = U x ⋅ V P x Cl_R = \frac{U_x \cdot V}{P_x} C l R ​ = P x ​ U x ​ ⋅ V ​ Where U x U_x U x ​ is urine concentration, V V V is urine flow rate, and P x P_x P x ​ is plasma concentration.

In Australian pharmacy practice, renal function is estimated using the Cockcroft-Gault equation to calculate creatinine clearance (CrCl): CrCl (mL/min) = ( 140 − Age ) ⋅ Weight (kg) ⋅ Constant Serum Creatinine (micromol/L) \text{CrCl (mL/min)} = \frac{(140 - \text{Age}) \cdot \text{Weight (kg)} \cdot \text{Constant}}{\text{Serum Creatinine (micromol/L)}} CrCl (mL/min) = Serum Creatinine (micromol/L) ( 140 − Age ) ⋅ Weight (kg) ⋅ Constant ​ Where the Constant is 1.23 for males and 1.04 for females. Weight is typically actual body weight unless the patient is obese, in which case adjusted body weight is used.

Half-life (t1/2) and Elimination Rate Constant (ke)

For drugs eliminated by first-order kinetics, a constant fraction of the drug is eliminated per unit time. The elimination rate constant ( k e k_e k e ​ ) represents the fractional rate of drug removal: k e = C l V d k_e = \frac{Cl}{V_d} k e ​ = V d ​ Cl ​

The elimination half-life ( t 1 / 2 t_{1/2} t 1/2 ​ ) is the time required for the plasma concentration to decrease by 50 % 50\% 50% : t 1 / 2 = ln ⁡ ( 2 ) k e ≈ 0.693 k e t_{1/2} = \frac{\ln(2)}{k_e} \approx \frac{0.693}{k_e} t 1/2 ​ = k e ​ ln ( 2 ) ​ ≈ k e ​ 0.693 ​

By substituting k e k_e k e ​ : t 1 / 2 = 0.693 ⋅ V d C l t_{1/2} = \frac{0.693 \cdot V_d}{Cl} t 1/2 ​ = Cl 0.693 ⋅ V d ​ ​

Important Clinical Concept: Half-life is a dependent variable, determined by the primary independent variables V d V_d V d ​ and C l Cl Cl . If V d V_d V d ​ increases (e.g., in sepsis or ascites, where fluid shift expands the distribution volume of hydrophilic drugs like gentamicin) or if C l Cl Cl decreases (e.g., in acute kidney injury), the half-life will prolong.

Steady-state Concentration (Css) and Maintenance Dose Calculations

Steady state ( C s s C_{ss} C ss ​ ) is reached when the rate of drug administration equals the rate of drug elimination: Rate of Drug Input = Rate of Drug Output \text{Rate of Drug Input} = \text{Rate of Drug Output} Rate of Drug Input = Rate of Drug Output

Time to Reach Steady State

The time to reach steady state is determined solely by the drug's half-life ( t 1 / 2 t_{1/2} t 1/2 ​ ). It is independent of the dose size or dosing frequency.

  • 1 half-life: 50 % 50\% 50% of steady state
  • 2 half-lives: 75 % 75\% 75% of steady state
  • 3 half-lives: 87.5 % 87.5\% 87.5% of steady state
  • 4 half-lives: 93.75 % 93.75\% 93.75% of steady state
  • 5 half-lives: 96.9 % 96.9\% 96.9% of steady state (clinically accepted as steady state)

Clinical Rule: A drug is considered fully washed out of the body after approximately 4–5 half-lives.

Average Steady-state Concentration ( C s s , a v g Css,avg C ss , a vg )

For multiple dosing regimens: C s s , avg = F ⋅ Dose C l ⋅ τ C_{ss,\text{avg}} = \frac{F \cdot \text{Dose}}{Cl \cdot \tau} C ss , avg ​ = Cl ⋅ τ F ⋅ Dose ​

Where τ \tau τ is the dosing interval.

Maintenance Dose (MD)

The maintenance dose is designed to maintain steady-state therapeutic concentrations: MD = C l ⋅ C target ⋅ τ F \text{MD} = \frac{Cl \cdot C_{\text{target}} \cdot \tau}{F} MD = F Cl ⋅ C target ​ ⋅ τ ​

Worked Clinical Example (Digoxin):

A 70-year-old female patient with a creatinine clearance of 40 mL/min (estimated digoxin clearance C l = 2.5 L/h Cl = 2.5 \text{ L/h} Cl = 2.5 L/h ) requires oral digoxin tablets ( F = 0.70 F = 0.70 F = 0.70 ) for heart failure. The target steady-state concentration is 0.8 micrograms/L. The dosing interval is 24 hours ( τ = 24 h \tau = 24 \text{ h} τ = 24 h ).

Calculate the daily maintenance dose: MD = 2.5 L/h ⋅ 0.8 micrograms/L ⋅ 24 h 0.70 \text{MD} = \frac{2.5 \text{ L/h} \cdot 0.8 \text{ micrograms/L} \cdot 24 \text{ h}}{0.70} MD = 0.70 2.5 L/h ⋅ 0.8 micrograms/L ⋅ 24 h ​ MD = 48 micrograms 0.70 ≈ 68.6 micrograms \text{MD} = \frac{48 \text{ micrograms}}{0.70} \approx 68.6 \text{ micrograms} MD = 0.70 48 micrograms ​ ≈ 68.6 micrograms

Clinical Context: Standard digoxin tablet sizes in Australia are 100 micrograms (0.1 mg) and 250 micrograms (0.25 mg). To approximate this calculated dose, the clinician may prescribe 100 micrograms daily, or 50 micrograms daily (using half a 100-microgram tablet) depending on age and clinical response, with subsequent therapeutic drug monitoring (TDM).

  • Accumulation Factor (R) and Area Under the Curve (AUC)
  • Accumulation Factor (R)

When drug doses are repeated at intervals ( τ \tau τ ) shorter than 4–5 half-lives, the drug accumulates in the body. The accumulation factor ( R R R ) describes the ratio of the steady-state concentration to that observed after the first dose: R = 1 1 − e − k e ⋅ τ R = \frac{1}{1 - e^{-k_e \cdot \tau}} R = 1 − e − k e ​ ⋅ τ 1 ​

If the dosing interval equals the half-life ( τ = t 1 / 2 \tau = t_{1/2} τ = t 1/2 ​ ), then e − k e ⋅ τ = e − ln ⁡ ( 2 ) = 0.5 e^{-k_e \cdot \tau} = e^{-\ln(2)} = 0.5 e − k e ​ ⋅ τ = e − l n ( 2 ) = 0.5 : R = 1 1 − 0.5 = 2 R = \frac{1}{1 - 0.5} = 2 R = 1 − 0.5 1 ​ = 2 This means that peak and trough levels at steady state will be exactly double the peak and trough levels observed after the first dose.

Relationship between Loading Dose and Maintenance Dose: LD = MD ⋅ R = MD 1 − e − k e ⋅ τ \text{LD} = \text{MD} \cdot R = \frac{\text{MD}}{1 - e^{-k_e \cdot \tau}} LD = MD ⋅ R = 1 − e − k e ​ ⋅ τ MD ​ If τ = t 1 / 2 \tau = t_{1/2} τ = t 1/2 ​ , then LD = 2 ⋅ MD \text{LD} = 2 \cdot \text{MD} LD = 2 ⋅ MD .

Area Under the Curve (AUC)

AUC represents the total drug exposure over time and is measured in units of concentration ⋅ \cdot ⋅ time (e.g., mg ⋅ \cdot ⋅ h/L).

It is calculated using the trapezoidal rule from plasma concentration-time profiles.

AUC is directly proportional to bioavailability and dose, and inversely proportional to clearance: AUC = F ⋅ Dose C l \text{AUC} = \frac{F \cdot \text{Dose}}{Cl} AUC = Cl F ⋅ Dose ​